GO
Loading...

Medicine

More

  • Genentech-A-Go-Go: Our Lips Are Sealed Wednesday, 15 Oct 2008 | 10:03 AM ET
    Genentech Earnings

    On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.

  • The Last Word--For Now--On Dendreon Wednesday, 8 Oct 2008 | 10:55 AM ET

    Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.

  • Roche Speaks My Language But Genentech Not So Much Tuesday, 7 Oct 2008 | 11:59 AM ET

    In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.

  • Could The Credit Crisis Help Pfizer? Monday, 6 Oct 2008 | 3:46 PM ET

    Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).

  • Biotech Bonanza For ImClone & Dendreon Monday, 6 Oct 2008 | 10:56 AM ET

    Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.

  • Dendreon, ImClone & Pfizer: Your Emails Friday, 3 Oct 2008 | 10:37 AM ET

    As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.

  • While the Street is focused on the big vote in the Senate tonight on the bailout package, biotech investors will be on the lookout for news out of ImClone Systems. Earlier this week the company announced that its mystery counter-bidder will decide whether to follow through on its $70-a-share offer by midnight tonight.

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • Mardi Gras Beads

    There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.

  • As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."

  • Pfizer Is A Driver: "Complaining" Investor Read On! Thursday, 18 Sep 2008 | 4:40 PM ET

    The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.

  • Lilly Loves Lechleiter--But Stock Moves On Other "News" Thursday, 18 Sep 2008 | 11:33 AM ET

    New Eli Lilly CEO John Lechleiter today joins the list of the recent fresh crop of big pharma honchos who've been elevated to Chairman of the Board as well. But that's not what's moving shares of LLY higher this morning.

  • Abbott & Boston Scientific: Rising Stent Stars Wednesday, 17 Sep 2008 | 12:21 PM ET
    Boston Scientific Corp.

    Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

  • Putting My Finger On The BlackBerry Addiction Friday, 12 Sep 2008 | 2:03 PM ET

    Yesterday afternoon I became a statistic. I am now among the reportedly growing number of people getting injured while texting and--not driving--but walking.

  • ImClone-Bristol Battle Is Really Gettin' Good Friday, 12 Sep 2008 | 9:57 AM ET

    I finished my last ImClone Systems vs. Bristol-Myers Squibb entry asking what Bristol had to say about IMCL's claim of a mystery outbidder. Well, yesterday we found out in a press release from BMY.

  • Pfizer: A Delay And A Deal? Tuesday, 9 Sep 2008 | 12:06 PM ET

    At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.

  • Pharma Stocks

    John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.

  • Lilly's Brewing Battle With Bristol And Your Emails Friday, 5 Sep 2008 | 12:58 PM ET
    Effient Ad

    Earlier this week I blogged about Eli Lilly's "Coming Soon" banner ad I spotted in the online edition of "The New England Journal of Medicine." It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month.

  • At The End Of The Day: Dendreon Thursday, 4 Sep 2008 | 4:30 PM ET

    Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.